pIE1-neo DNA - Novagen

The pIE1-neo plasmid is designed for the establishment of stably-transformed insect cells. When co-transfected with a pIE1 vector containing a foreign gene under the control of the baculovirus ie1 promoter, stable cell lines that constitutively express low levels of the target gene can be selected in the presence of the antibiotic G418 (1). The neo gene is expressed from an "unenhanced" ie1 promoter in pIE1-neo.

1. Jarvis, D.L., Weinkauf, C. and Guarino, L.A. (1996) Prot. Exp. Pur. 8, 191–203.

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)

This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the “EMD Product”) requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.